País: Tanzânia
Língua: inglês
Origem: Tanzania Medicinces & Medical Devices Authority
Ixazomib
Takeda Pharma AS, Denmark, DENMARK
Ixazomib
2.3 mg
Tablets
Haupt Pharma Amareg GmbH, GERMANY
Physical description: Light pink, size 4 hard gelatin capsule, marked ‘‘Takeda’’ on the cap and ‘‘2.3 mg’’ on the body with black ink; Local technical representative: Phillips Pharmaceuticals (Tanzania) Limited (2404)
Registered/Compliant
2019-08-02
Summary of Product Characteristics 1. Name of the medicinal product NINLARO 2.3 mg hard capsules 2. Qualitative and quantitative composition NINLARO 2.3 mg hard capsules Each capsule contains 2.3 mg of ixazomib (as 3.3 mg of ixazomib citrate) For the full list of excipients, see section 6.1. 3. Pharmaceutical form Hard capsule. NINLARO 2.3 mg hard capsules Light pink, size 4 gelatin hard capsule, marked “Takeda” on the cap and “2.3 mg” on the body with black ink. 4. Clinical particulars 4.1 Therapeutic indications NINLARO in combination with lenalidomide and dexamethasone is indicated for the treatment of adult patients with multiple myeloma who have received at least one prior therapy. 4.2 Posology and method of administration Treatment must be initiated and monitored under the supervision of a physician experienced in the management of multiple myeloma. Posology The recommended starting dose of ixazomib is 4 mg administered orally once a week on Days 1, 8, and 15 of a 28-day treatment cycle. The recommended starting dose of lenalidomide is 25 mg administered daily on Days 1 to 21 of a 28-day treatment cycle. The recommended starting dose of dexamethasone is 40 mg administered on Days 1, 8, 15, and 22 of a 28-day treatment cycle. Dosing schedule: Ixazomib taken with lenalidomide and dexamethasone 28-day cycle (a 4-week cycle) Week 1 Week 2 Week 3 Week 4 Day 1 Days 2 to 7 Day 8 Days 9 to 14 Day 15 Days 16 to 21 Day 22 Days 23 to 28 Leia o documento completo